Ranking Profile - Curis Inc

Introduction

Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating cancers with substantial unmet medical need. The company’s lead product Erivedge has been developed in collaboration with F. Hoffmann-La Roche Ltd and Genentech, which is commercialized for the treatment of advanced basal cell carcinoma (BCC). The product is approved for use in patients with advanced BCC in the US, European Union (EU), Australia and several other countries. The company has four drug candidates in development, Fimepinostat (previously CUDC-907) for treating diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-170 for advanced solid tumors or lymphoma; CA-4948 for treating non-Hodgkin lymphomas, and CI-8993 a human IgG1 kappa monoclonal antibody directed against VISTA including PD-1 and PD-L1 for treatment of cancer. Curtis is headquartered in Lexington, Massachusetts, the US.